-
HIV/AIDS - Research and Palliative Care
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Long-term treatment of patients with HIV-1: the role of atazanavir
Review
(1679) Views (581) Full article downloads
Authors: Miguel Ángel Artacho, Pablo Barreiro, José Vicente Fernández-Montero
Published Date September 2010
Volume 2010:2 Pages 157 - 166
DOI: http://dx.doi.org/10.2147/HIV.S5069
Miguel Ángel Artacho1, Pablo Barreiro2, José Vicente Fernández-Montero21Department of Internal Medicine, Hospital Universitario Gregorio Marañón, Madrid, Spain; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
Background: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been achieved in recent years.
Objective: To summarize and update evidence-based information about atazanavir (ATV) on initial, simplification, and rescue interventions in HIV patients.
Methods: Review of observational and randomized trials reported in medical conferences, peer-reviewed journals, and treatment guidelines.
Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients or after virological failure. Indulgent metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the long-term management of HIV infection.
Keywords: atazanavir, HAART, protease inhibitors
Readers of this article also read:
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The prevalence of human immunodeficiency virus infection among TB patients in Port Harcourt Nigeria
Atherosclerosis: pathogenesis and increased occurrence in individuals with HIV and Mycobacterium tuberculosis infection
Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives?
Strategies to improve HIV treatment adherence in developed countries: clinical management at the individual level
The use of preexposure treatments for HIV prophylaxis
Reproductive health options among HIV-infected persons in the low-income Niger Delta of Nigeria
Considerations in using text messages to improve adherence to highly active antiretroviral therapy: a qualitative study among clients in Yaoundé, Cameroon
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Treatment of drug-resistant tuberculosis
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India




